Scinai Bioservices receives NIS 809K grant for fill and finish capabilities expansion.

Scinai Bioservices has been awarded a non-dilutive grant of NIS 809,000 ($246,000) from the Israel Innovation Authority to fund a NIS 1.23 million ($373,000) project for acquiring and installing an advanced fill-and-finish system for sterile manufacturing. The grant will address a critical need among early-stage biotech companies in Israel and abroad by strengthening Scinai Bioservices' small-batch fill and finish capabilities.

Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI), a biopharmaceutical company with a growing boutique contract development and manufacturing organization (CDMO) business unit, Scinai Bioservices, has been awarded a non-dilutive grant of approximately NIS 809,000 (about $246,000) from the Israel Innovation Authority (IIA) Scinai Awarded Israel Innovation Authority Grant to Expand Fill-and-Finish CDMO Capabilities^[1]. The grant will fund approximately 66% of a NIS 1.23 million ($373,000) project aimed at acquiring and installing an advanced fill-and-finish system for sterile manufacturing.

This investment addresses a major industry gap, as many early-stage biotech companies in Israel lack access to local, flexible, small-scale GMP manufacturing. The advanced fill-and-finish system, designed to accommodate diverse primary packaging formats with minimal reconfiguration, will enable rapid batch turnaround and efficient switching between campaigns, significantly enhancing Scinai's fill-and-finish capacity and operational flexibility.

The IIA's decision recognizes Scinai's leadership in building Israel's biopharma manufacturing infrastructure. The grant will support Scinai's CDMO operations, which offer end-to-end, flexible CDMO solutions to clients in Israel, the U.S., and Europe. Since initiating CDMO operations in 2023, Scinai Bioservices has provided high-quality manufacturing and development support to numerous Israeli and international biotech companies.

The planned expansion, supported by the IIA grant, will further strengthen Scinai's ability to provide agile, small-batch, end-to-end CDMO services to biotech innovators in Israel and worldwide, fully compliant with EMA and FDA cGMP standards. Installation and qualification of the new filling system are expected in Q1 2026, with commercial operation planned for Q2 2026.